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Fatigue is one of the most common symptoms of multiple sclerosis. Despite advances
in pharmacological and non-pharmacological treatment, fatigue continues to be the dis-
abling symptom in persons with MS (pwMS), affecting almost 80% of pwMS. In current
practice, both pharmacological and non-pharmacological interventions are used in combi-
nation, encompassing a multi-disciplinary approach.The body of research investigating the
effect of these interventions is growing. This review systematically evaluated the existing
evidence on the effectiveness and safety of different interventions currently applied for the
management of fatigue in person with multiple sclerosis in improving patient outcomes,
to guide treating clinicians.
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BACKGROUND
Multiple sclerosis (MS), a chronic progressive demyelinating dis-
ease of the central nervous system (CNS), is the commonest cause
of chronic neurological disability in young adults (1, 2). It affects
approximately 2.5 million persons worldwide and the prevalence
of MS in Australia is estimated to be over 20,000 (95.2 per 100,000)
persons (2, 3). MS is complex and the exact pathogenesis is unclear.
Fatigue is one of the most common symptoms of MS, affecting
almost 80% of persons with MS (pwMS) (2), with 55% of pwMS
describing it as one of the worst symptoms they experience (1).
Fatigue is defined as “a subjective lack of physical or mental energy
that is perceived by the individual or caregiver to interfere with usual
and desired activities” (4). The definitive cause of fatigue in MS
is currently unknown, however, it is postulated that MS-related
fatigue may result from centrally mediated processes character-
ized by MS itself, such as demyelination and axonal loss in the
CNS or immune actions (Primary fatigue) or from MS-related
complications (trigeminal neuralgia, spasms, psychological issues,
etc.), musculoskeletal problems (pain, posture, gait anomalies,
etc.), sleep problems, and medications (Secondary fatigue) (5, 6).
Experimental studies have shown that fatigue results from reduced
voluntary activation of muscles by means of central mechanisms
(5). In general, fatigue is a poorly defined construct and hence dif-
ficult to measure (7). The MS International Federation recognized
two types of fatigue in pwMS, namely: physical or motor fatigue
(muscle weakness, slurred speech, unable to perform daily tasks,
etc.) and cognitive fatigue (deterioration of cognitive function such
as, reduced reaction time response, alertness during the day, dif-
ficulty in thinking, concentration, memory, recall, word finding,
etc.) (7, 8). Further, fatigue can be acute (newly occurring in the
past 6 weeks) or chronic (lasting longer than 6 weeks) (4). Brañas
et al. classifies fatigue experienced by pwMS into: “fatigability”
(increased weakness with exercise or as the day progresses) and
“lassitude” (abnormal constant and persistent sense of tiredness)
(9). In contrast to fatigue in normal people, MS-related fatigue
has distinctive characteristics, including: occurs on a daily basis;
worse as day progresses; aggravated by heat and humidity; comes
on more easily and suddenly; more severe than normal fatigue; and
more likely to interfere with role performance and physical func-
tioning (2, 9). Clinically, fatigue may manifest as exhaustion, lack
of energy, increased somnolence, or worsening of MS symptoms
and activity, and heat typically can exacerbate symptoms (6). The
mechanism for fatigue in MS is not known and several different
factors are believed to contribute to fatigue (Box 1).
Fatigue is prevalent in the MS population and a significant
health problem, adversely impacting on activities of daily living,
ability to work, social life, and quality of life (QoL) (4). Fatigue
has been associated with increased cognitive impairment and on a
person’s participatory roles (such as relationships and social inte-
gration, etc.) (11). There is strong consensus in literature that
many psychosocial factors influence adjustment to fatigue, includ-
ing the family’s response, coping behaviors, psychological distress,
and fatigue-related disability (1, 5). Fatigue is also associated with
poorer general health, increased disability, and higher rates of
health care utilization (12, 13). In a descriptive study of MS-related
disability (n= 101), 81% reported fatigue, with those in higher
fatigue grades reporting more disability and health care visits, and
lower QoL (14). In another study (n= 656 patients), 22% reported
limitation in level of physical activity, 14% stated it required them
to have more frequent rest breaks, and 10% had to discontinue
work due to fatigue (15).
Multiple sclerosis can have a fluctuating and often progressive
course, making symptomatic management more challenging. The
key to symptomatic management of pwMS, including fatigue, is
achievement of individualized, patient-centered goals that are set
collaboratively with patients, their carers, and the rehabilitation
team in a functional context, and should be based on the med-
ical and functional status of each patient (16–18). The quality and
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Box 1 Primary and secondary factors in Multiple Sclerosis fatigue.
Primary Factors
• Immune dysregulation – changes in neuroendocrine function.
• Central nervous system mechanisms – neuronal dysfunction due to immune injury, demyelination and inflammation, impaired innervation,
and activation of muscle groups leading to compensatory increase in central motor drive exertion and more energy depletion.
• Endocrine factors – abnormalities in hypothalamic/pituitary/adrenal axis.
• Neurotransmitter dysregulation – dopaminergic, histaminergic, and serotonergic pathways may contribute to fatigue.
Secondary Factors
• Physical deconditioning from failure to get adequate exercise.
• Sleep dysfunction – may also be due to nocturnal spasms, pain, incontinence, and depression.
• Pain – sensory disturbances, neuralgia, dysesthesia, and spasms.
• Psychological factors – lack of self-efficacy may increase feelings of fatigue.
• Depression – closely related to poor sleep, pain, and fatigue.
• Medications – can worsen fatigue [antispasticity agents, e.g., Baclofen].
Adapted from MacAllister and Krupp and Kos et al. (5, 10).
quantity of fatigue, and its impact on function is obtained in the
patient assessment and history. All contributing factors to fatigue
should be identified, and other non-MS causes should be excluded
and/or treated appropriately (4). A number of instruments exist
in MS literature for the assessment of fatigue and can be subjective
(self-reported by patients) and objective (quantified by clinicians
through various parameters) (10). Subjective or patient-reported
instruments are specifically designed to incorporate a patient’s
viewpoint and are more practical for use in clinical settings (10,
19). A list of commonly used subjective measures of MS-related
fatigue is provided in Table 1.
The published National Institute for Clinical Excellence (NICE)
clinical practice guidelines on the management of MS (26) high-
lights the significance of diagnosing and treating fatigue as part
of the management plan. A clinical decision-making flowchart for
managing fatigue in MS (10) is shown in Figure 1. Both pharma-
cological and non-pharmacological interventions individually or
in combination are recommended for the management of fatigue
in pwMS. Evidence supporting the efficacy of these interventions
in MS-related fatigue is still ambiguous and insufficient (5, 9). The
published guidelines acknowledge that the recommendations were
mostly driven by the expert opinions rather than by high-quality
research-derived evidence (26). Further, interventions for fatigue
management in pwMS are still not prescribed in a systematic
way (9).
The most commonly used agents for pharmacological treat-
ment for fatigue in pwMS include amantadine, modafinil,
and pemoline (9). The NICE guidelines (26) concluded that
the efficacy of any pharmacological agents specifically to treat
neurological fatigue is yet to be established. Many argue that non-
pharmacologic approaches used in isolation and/or in combina-
tion with pharmacological agents are the mainstay in the manage-
ment of fatigue in pwMS (9, 10). Non-pharmacological interven-
tions may include education (e.g., avoid heat, use air conditioners,
and cooling gel vests); address lifestyle factors (e.g., diet and exer-
cise; avoid physical activity at midafternoon); pacing (regular rest
breaks between activities); energy conservation and work simplifi-
cation strategies (e.g., use of assistive devices, adaptive equipment,
gait aids), and improve aerobic capacity and endurance (e.g.,
structured exercise programs).
Despite advances in pharmacological and non-pharmacological
treatment, MS-related fatigue continues to be the common dis-
abling symptom in pwMS. In current practice, both pharmaco-
logical and non-pharmacological interventions are used in combi-
nation, encompassing a multi-disciplinary approach. The body of
research investigating the effect of these interventions on manage-
ment of fatigue in MS is growing. The benefit and harms associated
with most of these interventions in pwMS needs to be established
comprehensively to guide treating clinicians. Therefore, the aim
of this review is to systematically evaluate the existing evidence
to investigate the effectiveness and safety of interventions for the
management of fatigue in pwMS in improving patient outcomes.
METHODS
An integrated approach was used, which included a comprehensive
review of literature (peer review and gray literature) document-
ing interventions currently used in management of fatigue in MS.
A comprehensive search of the literature published was under-
taken till 6th June 2014 using Medline, Embase, PubMed, and
Cochrane Library databases. The search strategy included inter-
ventional studies investigating management of fatigue in pwMS,
using combinations of multiple search terms for three themes:
MS, interventions (pharmacological and non-pharmacological),
and fatigue. Medical subject heading (MeSH) search terms were
used for all databases and a keyword search was used if the
MeSH term was not available. The bibliographies of identified
articles were scrutinized for additional references and a man-
ual search of relevant journals was undertaken. A gray litera-
ture search using different internet search engines and websites
such as: system for Information on Gray Literature in Europe;
New York Academy of Medicine Gray Literature Collection, and
Google Scholar, was also undertaken. Additional searches of the
websites of prominent national and international organizations
associated with MS management were conducted to identify rel-
evant reports, health technology assessments, or other related
materials.
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Table 1 | Commonly used subjective measures of MS-related fatigue.
Name of scale Reference Population Specified fatigue subscales No. of items Scoring
Modified fatigue impact
scale
Paralyzed Veterans
of America, 1998 (4)
MS Physical, cognitive, and
psychosocial
21 1–7 (Likert scale)
Rochester fatigue diary Schwid et al. (20) MS Lassitude [reduced energy] 12 0–100 (mm) visual
analog scale
Fatigue descriptive scale Iriarte et al. (21) MS Spontaneous mention of fatigue,
antecedent conditions, frequency,
impact on life
5 0–3 (Likert scale)
Fatigue impact scale Fisk et al. (22) MS Physical, cognitive, psychosocial 40 0–4 (Likert scale)
Fatigue assessment
instrument
Schwartz et al. (23) MS, chronic fatigue
syndrome, lupus,
dysthymia, healthy
Fatigue severity, situation
specificity, consequences of
fatigue, responds to rest/sleep
29 1–7 (Likert scale)
Single item visual analog
scale of fatigue
Krupp et al. (24) MS, lupus, healthy Depends on the question 1 0–100 (mm) visual
analog scale
Fatigue severity scale Krupp et al. (24) MS, lupus, healthy None 9 1–7 (Likert scale)
Fatigue scale for motor and
cognitive functions (FSMC)
Penner et al. (25) MS Motor and cognition 20 1–5 (Likert scale)
Adapted from MacAllister and Krupp (10) and Kos et al. (5).
INCLUSION CRITERIA
Studies that compared various interventions in management of
fatigue in pwMS with routinely available local services or lower
levels of intervention or placebo, or studies that compared such
interventions in different settings or at different levels of intensity,
were included. All systematic reviews, meta-analyses, random-
ized clinical trials (RCTs), and controlled clinical trials (CCTs),
quasi-randomized and quasi-experimental designs with com-
parative controls, and controlled before-and-after studies were
included. Whenever RCTs/CCTs were lacking, a search for rel-
evant observational studies was conducted. Studies involving
other medical conditions, where data were specifically provided
for MS-related fatigue, were also included. Descriptive studies
and narrative reviews were explored to identify policies, pro-
tocols, and gaps in service provision. Where high-quality sys-
tematic reviews or meta-analyses were identified, articles pub-
lished prior to the date of that review’s search strategy were
excluded.
EXCLUSION CRITERIA
Limits placed included English-language publication and inclu-
sion of adults aged 18 years and above. Theses, narrative reviews,
editorials, case reports, economic evaluation, conference proceed-
ings, and studies evaluating surgical intervention or diagnostic
procedures for MS-related fatigue were excluded.
STUDY SELECTION
Two authors (Bhasker Amatya and Mary Galea) independently
screened and shortlisted all abstracts and titles of studies identi-
fied by the search strategy for inclusion and appropriateness based
on the selection criteria. Each study was evaluated independently
by authors. If necessary, the full text of the article was obtained for
further assessment to determine whether the article met the inclu-
sion/exclusion criteria. If no consensus was reached regarding the
possible inclusion/exclusion of any individual study, a final con-
sensus decision was made by the third author (Fary Khan). Further
information about the complete description of the interventions
from the trialists was obtained, where necessary.
DATA EXTRACTION
Data extraction was conducted by two authors independently,
using a standard pro forma. The information obtained from all
included studies was: publication date and country, study location,
study design, intervention, outcome measures used, and fatigue-
related outcomes. Any discrepancies were resolved by all authors
re-reviewing the study.
Evidence for all included studies was categorized according to
study design using a hierarchy of evidence in descending order and
priority were given to the most recently published high-quality
systematic reviews or meta-analysis and RCT. Formal levels of evi-
dence were assigned using a standard format defined by National
Health and Medical Research Council (NHMRC) pilot program
2005–2006 for intervention studies (Table 2) (27).
RESULTS
The electronic database search retrieved 1673 published articles
on fatigue in MS; 428 articles met title inclusion criteria of which
55 articles met the abstract inclusion criteria and went on to full-
text review. Four articles that met the abstract inclusion criteria
were identified from the bibliographies of relevant articles. Over-
all, 27 studies (12 systematic reviews/meta-analyses, 12 RCTs, 2
CCT, and 1 comparative studies) fulfilled the inclusion criteria
for this review. The study selection process is summarized in the
PRISMA flow diagram shown in Figure 2.
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FIGURE 1 | Clinical decision-making flow chart for treating fatigue in MS. Adapted from MacAllister and Krupp (10).
EVIDENCE FOR PHARMACOLOGICAL INTERVENTIONS FOR FATIGUE IN
PERSONS WITH MS
Currently, different pharmacological agents are used for treatment
for fatigue in pwMS, which include amantadine, modafinil, and
pemoline (9, 11). Modafinil, a “wake promoting” agent that selec-
tively works in the hypothalamic pathways used in narcolepsy, has
been reported to improve fatigue in progressive MS (5, 9). The
efficacy of pemoline, a CNS stimulant, is still unclear (9, 28, 29).
Amino pyridines (potassium channel blockers) and amantadine
(N -methyl d-aspartate receptor antagonist) have been trialed;
however, systematic reviews failed to find evidence for efficacy
or safety for their use (30). There is empirical support for use of
antidepressants in MS-related fatigue, as depression is considered
to be one of the major contributing factors (31, 32).
A recently published comprehensive meta-analysis of differ-
ent interventions (pharmacological and non-pharmacological)
included seven RCTs evaluating different medications used for
the management of fatigue in pwMS. The authors found weak
and inconclusive beneficial effects of pharmacological interven-
tion for MS-related fatigue, with small and non-significant pooled
effect sizes (ESs) with a relatively narrow 95% CI (ES= 0.07,
95% CI: −0.22 to −0.37, p= 0.63) (11). The pharmacological
agents in this review were restricted to Amantadine and Modafinil.
Similar inconclusive and insufficient research-derived evidence
to support the various pharmacological treatments was reported
in another comprehensive systematic review of pharmacologi-
cal interventions for MS-fatigue published previously (9). The
authors systematically reviewed studies investigating only two
pharmacological agents: amantadine and pemoline. The studies
evaluating the effectiveness of amantadine (four RCTs) showed a
pattern in favor of amantadine compared with placebo; however,
there was considerable uncertainty about the validity and clinical
significance of this finding. Studies investigating efficacy of pemo-
line (n= two RCTs) demonstrated no overall tendency in favor
of pemoline over placebo (9). In addition, an excess of reports of
adverse effects was noted for pemoline.
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Table 2 | Designations of “levels of evidence” according to type of
research question (27) (intervention studies only).a
Level Intervention
I A systematic review of level II studies
II A randomized controlled trial
III-1 A pseudo-randomized controlled trial (i.e., alternate allocation or
some other method)
III-2 A comparative study with concurrent controls
• Non-randomized experimental trial
• Cohort study
• Case–control study
• Interrupted time-series with a control group
III-3 A comparative study without concurrent controls
• Historical control study
•Two or more single arm study
• Interrupted time-series without a parallel control group
IV Case series with either post-test or pre-test/post-test outcomes
aNote that our selection criteria exclude studies at level III-3 and IV.
One comprehensive systematic review exploring efficacy of dif-
ferent pharmacological treatments on non-specific fatigue in pal-
liative care included 10 studies investigating amantadine (n= 6),
pemoline, and modafinil in pwMS (33). The authors reported
mixed results with weak and inconclusive data. Amantadine (total
n= 6) was found to demonstrate some improvement in fatigue in
pwMS (meta-analysis of three-studies; standard mean difference
compared to placebo 1.68). Both pemoline (n= 3) and modafinil
(n= 2) failed to demonstrate a significant effect for management
of fatigue in pwMS (33).
Commonly used pharmacological agents for fatigue and MS
are summarized in Table 3, along with indications, doses, and side
effects.
Summary
Different pharmacological agents used for treatment of fatigue
in pwMS include Amantadine, Modafinil, and Pemoline. There is
however, insufficient research-derived evidence to support these
pharmacological agents for management of MS related fatigue.
EVIDENCE FOR NON-PHARMACOLOGICAL INTERVENTIONS FOR
FATIGUE IN PERSONS WITH MS
There is widespread agreement in the literature that, due to
the complex, multidimensional, and highly subjective nature of
MS-related fatigue, comprehensive goal orientated management
programs that incorporate multi-disciplinary (MD) expertise are
required, and patients need to be evaluated regularly through
appropriate clinical outcome measures (17, 18). The character-
istics of the all included studies evaluating non-pharmacological
interventions for fatigue in pwMS are summarized in Table 4.
MULTI-DISCIPLINARY REHABILITATION (LEVEL I EVIDENCE)
Existing clinical practice guidelines for MS recommend com-
prehensive, co-ordinated MD care, including symptomatic
management, and appropriate follow up, education, and support
for patients and carers (26). MD rehabilitation, a co-ordinated
delivery of patient-centered, time-based, functionally oriented
intervention/s by two or more disciplines (such as physiotherapy,
occupational therapy, social work, psychology, and other allied
health, nursing), under medical supervision (17), should be the
best approach in symptomatic management in MS, including
fatigue (5, 34). A systematic review of MD rehabilitation in MS
(17), found a “strong evidence” to support MD rehabilitation in
producing short-term gains at the levels of activity (disability)
and participation in patients with MS. Of the 10 included trials,
fatigue was considered in only two studies evaluating outpatient
and home-based rehabilitation programs. A CCT (35) evaluating
the influence of an extended MD outpatient rehabilitation found
that fatigue symptoms were significantly reduced in the treat-
ment group compared to the control group at 1-year follow-up
(p= 0.004). Similar result was reported in another RCT evaluat-
ing impact of outpatient MD rehabilitation. The authors reported
that a 12-week rehabilitation program significantly reduced fatigue
and improved social functioning and depression (p< 0.001) (36).
There was no convincing evidence regarding the effectiveness of
inpatient MD rehabilitation programs for management of fatigue
(17). An RCT investigating MD inpatient rehabilitation did not
find any significant benefits of such a program on disability level
or perceived fatigue (37).
SPECIFIC REHABILITATION INTERVENTIONS
The cause and effect of fatigue are considered to be multidimen-
sional and its impact extends from general everyday activity to
overall QoL of pwMS (11, 38). Improving or restoring physi-
cal and psychosocial abilities and education have been proposed
to counteract many MS-fatigue-related consequences. A reha-
bilitation approach to fatigue management in pwMS includes a
spectrum of interventions, which have been examined in several
published reviews. However, many of these interventions have not
yet been included routinely in comprehensive MD rehabilitation
programs, and few studies show their implementation. The exist-
ing evidence for various specific rehabilitation interventions for
fatigue management in pwMS is summarized below.
PHYSICAL THERAPEUTIC MODALITIES
Physical therapeutic modalities are considered to be one of the
most efficient strategies in rehabilitation of MS patients in improv-
ing or restoring physical abilities. However, its role in MS-related
fatigue management has been controversial. In past years, pwMS
were advised not to participate in physical activities because it
was believed to lead to worsening of symptoms or fatigue (15,
39, 40). However, recent studies on exercise therapy in MS have
demonstrated that it results in substantial long-term reduction in
functional limitations and enhanced QoL, and have the potential
to reduce fatigue in pwMS (39).
EXERCISE (LEVEL I)
Exercise therapy is a core rehabilitative measure, which aims
to improve motor functions (such as co-ordination, fine-
movements), balance, gait, and reduction of MS-related symp-
toms. Compared with the other interventions, exercise has been
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FIGURE 2 | PRISMA flow diagram showing selection of article review.
more frequently investigated for MS-related fatigue, which has
resulted in several systematic reviews/meta-analyses evaluating
various exercise modalities for the management of fatigue (11,
41–45). A wide range of exercise interventions were investigated,
which included resistance training, endurance training, aquatic
exercises, leisure activities, and a combination of two or more exer-
cise modalities. In a recently published systematic review, Asano
and Finlayson reported strong evidence for exercise-based reha-
bilitation in terms of reducing severity of patient-reported fatigue
(11). Although there was heterogeneity among the included tri-
als (n= 10 studies; p= 0.003), exercise interventions were still
found to have a significant beneficial effect in managing fatigue
in pwMS (pooled ES was 0.57; 95% CI: 0.10–1.04, p= 0.02).
The authors stated that the extent of the intervention effects var-
ied considerably and only a certain group of patients (younger,
with stable MS) appear to experience benefit. For other MS
subgroups, such as older adults or those with progressive MS
and/or severe disability, there was no evidence of benefit. Fur-
ther, it was not possible to identify which types or components or
intensity of exercise achieved benefits for fatigue management.
Another meta-analysis (n= 17 RCTs), demonstrated a similar
positive effect of exercise interventions for MS-related fatigue
(45). The authors showed that exercise training was associated
with a significant reduction in fatigue among pwMS (weighted
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Table 3 | Commonly used pharmacologic treatments for MS-related fatigue.
Drug Brand name FDA indications Dosage Common side effects
Amantadine Symmetrel® Influenza;
Parkinson’s Disease
100 mg BID • Livedo reticularis
• Orthostatic hypotension
• Peripheral edema
• Headache
• Dizziness
• Nausea
• Insomnia
Modafinil Provigil® Narcolepsy;
shift-work sleep
disorder; excessive
daytime sleepiness
from OSA not
relieved by CPAP
Start 200 mg every morning
or at start of shift, may
escalate to 400 mg
• Anxiety
• Headache
• Dizziness
• Nausea
• Hypertension
• Palpitations
• Insomnia
Armodafinil Nuvigil® See Modafinil Start at 150 mg every
morning or at start of shift,
may escalate to 250 mg
• See Modafinil
Pemoline Cylert® Attention deficit
hyperactivity
disorder (ADHD)
Starting at 37.5 mg/day and
gradually increased by
18.75 mg at 1 week intervals.
The maximum recommended
daily dose is 112.5 mg
• Hepatic dysfunction
• Insomnia
• Convulsive seizures
• Hallucinations
• Dyskinetic movements of the tongue, lips, face and extremities
• Abnormal oculomotor function
• Dizziness
• Increased irritability; headache; and drowsiness
• Anorexia and weight loss
• Nausea and stomach ache
Adapted from Braley and Chervin (6) and Branas et al. (9).
mean ES= 0.45; 95% CI= 0.22–0.68, p≤ 0.001) (45). A system-
atic review by Andreasen et al. assessed the beneficial effect of
different exercise categories separately; these included endurance
training, resistance training, combined, or “other” training modal-
ities (39). The authors, consistent with other reviews, found
marked heterogeneity among the trials, as only a few studies
evaluated MS fatigue as the primary outcome and many studies
included non-fatigued MS patients. Overall, all type of exercise
interventions were shown to have the potential to reduce MS
fatigue (39). The authors concluded that, compared to other
exercise modalities, endurance training was studied more fre-
quently (n= 11 studies) and showed more consistent positive
effects (39).
Several reviews evaluated exercise therapy for MS in general
(42, 44, 46) and reported strong evidence in favor of exercise ther-
apy compared to no exercise therapy, in terms of muscle power,
exercise tolerance, and mobility-related activities. Conversely, sub-
group analysis of results on fatigue showed mixed results. One
study found that neurophysiologically based physiotherapy or a
combined training program (physiotherapy plus aerobic training)
were associated with significant improvement in impairment and
fatigue (47).
Summary
Overall, the evidence regarding exercise modalities for MS-related
fatigue was inconsistent and data for an optimal type or inten-
sity of exercise intervention are still insufficient. Some types of
exercise interventions which include endurance and a resistance-
training component may have potential beneficial effects on
fatigue reduction in pwMS.
AQUATIC THERAPY (LEVEL II)
Few studies have evaluated aquatic therapy, which aims to reduce
resistance of movements and gravity by exercising in water (pool
therapy, hydrotherapy, balneotherapy), for management of fatigue
in pwMS (48–52). There is evidence from two RCTs showing
beneficial effects of an aquatic exercise program for MS-related
fatigue. One RCT examined the effectiveness of a supervised 8-
week aquatic exercise training program (60 min session, three
times a week) on fatigue and health-related QoL in women
(n= 32) with MS (50). The participants in the aquatic exercise
group showed significant improvements in fatigue and QoL after
4 and 8 weeks compared with the control group (50). Another
RCT (n= 73) suggested that a structured aquatic exercise (Ai
Chi) program for 20 weeks (40 sessions) improved fatigue, pain,
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Table 4 | Non-pharmacological interventions for fatigue in MS.
Study, year
country
Study design Potential intervention Outcome measures
for fatigue
Main findings Level of
evidencea
MULTI-DISCIPLINARY (MD) REHABILITATION
Khan et al.
2011 (17, 31),
Australia
Systematic
review, n=10
trials (nine RCTs
and one CCT)
Extended MD outpatient
rehabilitation
Fatigue, frequency,
FIS; MS-related
symptom checklist
composite score
• Fatigue symptoms significantly
• Improved social functioning and depression
I
Inpatient MD rehabilitation MSIS29, VAS • No significant benefits on perceived fatigue or
disability level
PHYSICAL MODALITIES
Exercise
Asano and
Finlayson
2014 (11),
Canada
Meta-analysis,
n=10 RCTs
Various types of exercises
(progressive resistance,
aerobic, inspiratory
exercises, aquatic exercises,
vestibular rehabilitation, and
leisure exercises)
FSS, MFIS, FIS • Significant beneficial effect in managing
fatigue [pooled effect size (ES) was 0.57; 95%
CI: 0.10–1.04, p=0.02]
• ES for the exercise interventions range: −0.24
(95% CI: −1.15 to 0.64) to 2.05 (95% CI:
1.00–3.11)
I
Latimer-
Cheung et al.
2013 (42),
Canada
Systematic
review, n=54
trials (30
evaluating
fatigue
outcomes: 15
RCTs and 15
other design)
Aerobic fitness; muscle
strength (resistance training)
and combined
FSS, FIS, MFIS,
SF-36 (vitality
subscale), PMS
(energy and fatigue
subscales),
MSQL-54 (energy
subscale)
• Aerobic exercise: significant improvements in
some general fatigue symptoms but not
specific symptoms after 2–6 months of light to
moderate cycling for 40–60 min three
times/week; decreases in general, physical,
and psychological fatigue symptoms after
8 weeks of moderate-intensity aerobic
activities two times/week
III-1
•Traditional resistance training: improvements
in general symptomatic fatigue after a
12-week, two times/week resistance training
program (8–15 RM); decreased fatigue overall
or specifically physical and psychological
fatigue after 8 weeks of moderate-intensity
resistance training two times/week (6–15 RM)
• Combined training programs: significant
increase in vitality or decrease in fatigue
severity after 5–8 weeks of supervised aerobic
and resistance training performed at moderate
to high intensity; significant improvements in
fatigue symptoms or severity after 8–10 weeks
of two to three times/week combined training
• Other types of exercise (sport, yoga, body
weight support treadmill training, aquatic
exercise, cycling, and Pilates): a significant
decrease on at least one indicator of fatigue
(general or specific) symptoms
Andreasen
et al. 2011
(39),
Denmark
Systematic
review, n=21
trials (11 RCTs,
1 CCT, 9 other
design)
Endurance training,
resistance, training,
combined training, or
“other” training modalities
FSS, MFI, MFIS,
FCMC
• Exercise therapy on MS fatigue show
heterogeneous results and only few studies
have evaluated MS fatigue as the primary
outcome
III-1
• All type of exercise modalities have potential
to reduce MS fatigue
• Not clear whether any exercise modalities are
superior to others
(Continued)
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Table 4 | Continued
Study, year
country
Study design Potential intervention Outcome measures
for fatigue
Main findings Level of
evidencea
Neill et al.
2006 (43),
Australia
Systematic
review, n=11
trials [combined
for MS,
rheumatoid
arthritis (RA) and
systemic lupus
erythematosus
(SLE); various
study design]
Aerobic exercise, resistance
training
FIS, FSS, SF-36,
POMS, VAS,
• Aerobic exercise (home-based or supervised
classes) is effective in managing fatigue for
some people with MS, RA and SLE
III-1
• Six studies reported statistically significant
reductions in fatigue from aerobic exercise
interventions
• Low-impact aerobics, walking, cycling, and
jogging were effective interventions
Aquatic therapy
Kargarfard
et al. 2012
(50), Iran
RCT, n=32
women with
MS
Aquatic exercise: joint
mobility, flexor and extensor
muscle strength, balance
movements (60 min session
three times/week), control
group: usual care
MFIS, MSQL-54 • Patients in the aquatic exercise group showed
significant improvements in fatigue and QoL
after 4 and 8 weeks (p=0.002 and <0.001,
respectively)
II
Castro-
Sánchez
et al. 2012
(48), Spain
RCT, n=73
pwMS
Treatment group: aquatic
Tai-Chi (40 sessions)
(n=36); control group:
relaxation (n=37)
FSS, MFIS •Treatment group showed a significant score
reduction in fatigue at week 20 (p<0.032)
that was maintained at week 24 (p<0.038)
II
• An improvement was shown by 48% of the
treatment group
• Significant improvement in pain, spasms,
disability, fatigue, and depression was also
reported in treatment group
Bayraktar
et al. 2013
(53), Turkey
CCT, n=23
pwMS
Treatment group: aquatic
Tai-Chi (n=15); control
group: exercise at home
(n=8)
FSS • Significant in reduction in fatigue in the
treatment group (p<0.05)
III-1
• Improvement in balance, functional mobility,
upper and lower extremity muscle strength
was also noted in treatment group (p<0.05)
Tai chi
Castro-
Sánchez
et al. 2012
(48), Spain
RCT, n=73
pwMS
Treatment group: aquatic
Tai-Chi (40 sessions)
(n=36); control group:
relaxation (n=37)
FSS, MFIS See “Aquatic Therapy” section above II
Bayraktar
et al. 2013
(53), Turkey
CCT, n=23
pwMS
Treatment group: aquatic
Tai-Chi (n=15); control
group: exercise at home
(n=8)
FSS See “Aquatic Therapy” section above III-1
Mills et al.
2000 (56),
UK
Comparative
study, n=8
pwMS
Tai Chi/QiGong along with
the teaching QiGong
self-massage. TuiNa and
daily home practice for
30 min
POMS, 21-Item
symptom checklist
• Significant improvements in fatigue post
intervention
III-2
Cooling devices
Beenakker
et al. 2001
(57),
Netherlands
RCT, n=10 Wearing cooling garment for
60 min at 7°C (active
cooling); control group: 26°C
(sham cooling).
MFIS • Beneficial effect of cooling therapy in reducing
fatigue, improving postural stability and
muscle strength in pwMS
II
(Continued)
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Table 4 | Continued
Study, year
country
Study design Potential intervention Outcome measures
for fatigue
Main findings Level of
evidencea
White et al.
2000 (58),
USA
RCT, n=6
pwMS
Immersing participants’
lower body regions in water
baths at 16–17°C for 30 min
before training
FIS • Reduced fatigability during training sessions
(p<0.05)
II
• Fewer heat-induced symptoms such as ataxia,
blurred vision, and foot drop during exercise
preceded by cooling
Pulsed electro-magnetic devices
Lappin et al.
2003 (60),
USA
RCT, n=117
pwMS
“Enermed” – active
low-level, pulsed
electro-magnetic field
device worn up to 24 h daily
on one or more acupressure
points for up to 4–8 weeks
MSQLI • Statistically significant decreases in fatigue for
the intervention groups (0.05)
II
• Overall QoL significantly greater on the active
device group
• No treatment effects for bladder control and a
disability composite, and mixed results for
spasticity
Richards
et al. 1997
(61), USA
RCT, n=33
pwMS
“Enermed” – see above Patient-reported
performance scales
• Significant improvement in the performance
scale (PS) combined rating for bladder control,
cognitive function, fatigue level, mobility,
spasticity, and vision (active group
–3.83±1.08, p<0.005; placebo group
–0.17±1.07, change in PS scale)
II
BEHAVIORAL AND EDUCATIONAL INTERVENTIONS
Asano and
Finlayson
2014 (11),
Canada
Meta-analysis,
n=8 RCTs
Various types of psychologi-
cal/educational interventions
(fatigue management
program, energy
conservation course, CBT,
mindfulness intervention)
FSS, MFIS, FIS • Significant beneficial effect in managing
fatigue [pooled effect size (ES) was 0.54; 95%
CI: 0.30–0.77, p<0.001]
I
• ES for the educational interventions range:
from -0.16 (95% CI: -0.72 to 0.38) to 1.11
(95% CI: 0.43 to 1.78)
Neill J et al.
2006 (43),
Australia
Systematic
review, n=15
trials (combined
for MS, RA and
SLE; various
study design
design)
Education programs, energy
conservation,
self-management, fatigue
management program, CBT
FIS, FSS, SF-36,
POMS, VAS,
• Behavioral interventions appeared effective in
reducing fatigue
III-2
• Education alone or with exercise reduced
fatigue and increased vitality in pwMS
• Rehabilitation program and counseling were
effective in reducing fatigue
Fatigue management programs
Thomas et al.
2013 (70), UK
RCT, n=164
pwMS
Group-based interactive
program for managing
MS-fatigue [fatigue: applying
cognitive behavioral and
energy effectiveness
techniques to lifestyle
(FACETS] (90-min sessions
weekly for 6 weeks facili-
tated by two health pro-
fessionals (n=84); control
group (n=80) usual care)
FAI, MSFS • At 1-month post intervention: significant
differences favoring the intervention group on
fatigue self-efficacy (mean difference=9;
95% CI 4–14; ES=0.54, p=0.001).
II
• At 4 months follow-up: positive effects of the
program still remained significant with
moderated effect size (ES=0.36; p=0.05;
mean difference=6; 95% CI 0–12); significant
improvement in fatigue severity was also
found in intervention group (p=0.01)
Thomas et al.
2014 (64), UK
RCT, n=164
pwMS
Same as above Same as above • At 1-year follow-up: benefits of the FACETS
program for fatigue severity and self-efficacy
mostly sustained (ES= -0.29, p=0.06 and
0.34, p=0.09, respectively); additional
significant improvements in QoL (p=0.046)
II
(Continued)
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Table 4 | Continued
Study, year
country
Study design Potential intervention Outcome measures
for fatigue
Main findings Level of
evidencea
Kos et al.
2007 (34),
Belgium
RCT, n=51
pwMS
Multi-disciplinary fatigue
management program:
interactive educational
sessions about possible
strategies to manage fatigue
and reduced energy levels
(four 2 h sessions/week)
(n=28); control group:
placebo
MFIS • No efficacy in reducing the impact of fatigue
compared to a placebo intervention program
(ES=−0.16)
II
Energy conservation interventions
Blikman et al.
2013 (65),
Netherlands
Systematic
review, n=6
trials (four RCTs
and two CCTs)
Energy conservation
interventions: education
about balancing, modifying
and prioritizing activities,
rest, self-care, effective
communication,
biomechanics, ergonomics,
and environmental
modification
FIS • Energy conservation interventions were more
effective than no treatment in improving
subscale scores of FIS: cognitive mean
difference (MD=−2.91; 95% CI, −4.32 to
−1.50), physical (MD=−2.99; 95% CI, −4.47
to −1.52), and psychosocial (MD=−6.05;
95% CI, −8.72 to −3.37)
I
• QoL scores on physical, social function and
mental health (also improved significantly in
treatment group
• None of the studies reported long-term results
Mindfulness-based interventions
Simpson
et al. 2014
(66), UK
Systematic
review, n=3
trials (two RCTs
and one CCT)
Mindfulness-based
interventions: mindful
breath awareness, mindful
movement, and body
awareness or “scanning”
MFIS, POM • Significantly beneficial effect on fatigue scores I
• One RCT found significant post-intervention
reduction in fatigue in both overall population
and in subgroup analyses of those with
pre-intervention impairment (p<0.001 for
both).
• Beneficial effect maintained at 6 months
Cognitive and psychological interventions
Moss-Morris
et al. 2012
(68), UK
RCTn=40
pwMS
Intervention group (n=23):
internet-based cognitive
behavior therapy
(CBT) – “MS Invigor8” (eight
tailored, interactive sessions
with a clinical psychologist
over 8–10 weeks)Control
group (n=17): standard care
MFIS • Significant greater improvements in fatigue
severity and impact; and also in anxiety,
depression and quality-adjusted life years in
treatment group
II
van Kessel
et al. 2008
(69), New
Zealand
RCTn=72 Treatment group (n=35):
CBT (eight weekly
sessions)Control group
(n=37): relaxation therapy
CFS, MFIS • Both groups showed clinically significant
decreases in fatigue
II
• Significantly greater improvements in fatigue
in treatment group (p<0.02) compared to
relaxation therapy group: ES=3.03 (95% CI
2.22–3.68) for the CBT group across 8 months
compared with the relaxation therapy group
(ES 1.83; 95% CI 1.26–2.34)
aLevels of evidence’ categorized according to National Health and Medical Research Council (NHMRC) pilot program 2005–2006 for intervention studies (23).
CBT, cognitive behavioral therapy; CCT, clinical controlled trial; CFS, Chalder fatigue scale; ES, effect size; 95% CI, 95% confidence interval; FAI, fatigue assessment
instrument; FSMC, fatigue scale for motor and cognitive functions; FSS, fatigue severity scale; FIS, fatigue impact scale; MFIS, modified fatigue impact scale; MSFS,
multiple sclerosis-fatigue self-efficacy; MSIS, multiple sclerosis impairment scale; MSIS29, multiple sclerosis impact scale; MSQL-54, multiple sclerosis quality of
life-54 MFI, multidimensional fatigue inventory; POMS, profile of mood states; QoL, quality of life; RCT, randomized controlled trial; SF-36, short-form health survey-36,
VAS, visual analog scales.
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spasms, disability, and depression in pwMS (48). Bayraktar et al.
investigated the effects of a similar aquatic exercise program (Ai
Chi) in a CCT (n= 23) on balance, functional mobility, strength,
and fatigue in ambulatory pwMS (53). The authors reported
significant improvements in fatigue, static standing balance, func-
tional mobility, and upper and lower extremity muscle strength in
the treatment group (p< 0.05) (53).
Summary
Aquatic exercise training can improve fatigue and other MS-
related symptoms, function and quality of life of pwMS and could
be considered for inclusion in management programs.
TAI CHI (LEVEL II)
Tai Chi is gaining momentum in rehabilitation settings and can
improve balance, posture, muscle strength, psychological issues
(stress reduction, and decreased anxiety, depression and mood
disturbance) and general well-being in people with various med-
ical conditions (54, 55). The effects of Tai Chi on fatigue in pwMS
have been evaluated in only a few studies. Two trials (one RCT
and one CCT) (also reported under aquatic exercise) investigated
the effectiveness of Tai Chi aquatic exercise program in reduc-
ing symptoms, including fatigue and improving physical function
in pwMS (48, 53). There was a significant reduction in fatigue
in individuals with MS participating in the Tai Chi classes as
compared to the control group (see above in section “Aquatic
Therapy”). Another comparative study found that practicing Tai
Chi for 2 months daily was associated with some improvements
in fatigue and significant improvements in balance and depressive
symptoms in pwMS (56).
Summary
There is limited evidence suggesting the effectiveness of Tai chi
in improving fatigue symptoms in pwMS. Further studies with a
larger sample size are needed to confirm the potential effectiveness
of Tai chi in fatigue management in pwMS.
COOLING THERAPY (LEVEL II)
Physiological approaches such as cooling techniques using differ-
ent cooling temperatures and durations have been tested for symp-
tomatic management in heat-sensitive pwMS. Beenakker et al.
conducted a RCT showing a beneficial effect of cooling therapy in
reducing fatigue, improving postural stability, and muscle strength
in pwMS when wearing a cold vest with active cooling (7°C,
60 min) (57). Another study investigating the effects of immers-
ing participants’ lower body regions in water baths at 16–17°C for
30 min before training, found that fatigability significantly reduced
in these patients during training sessions (58). These effects of
cooling on functional improvements are most probably due to
temperature-induced changes (Uhthoff phenomenon) in central
motor conduction in demyelinated fibers (59).
Summary
Pre-cooling or cooling during and after therapy may decrease
fatigue and increase the effect of active physical training in thermo
sensitive pwMS. However, the evidence is limited and unclear. Fur-
ther research is required to identify who will benefit from these
techniques.
PULSED ELECTRO-MAGNETIC DEVICES (LEVEL II)
Low-level pulsed electro-magnetic field devices have been inves-
tigated in a few trials and have shown positive effects in reducing
for MS-related fatigue (60–62). A multi-center RCT (n= 117)
found that wearing an active low-level, pulsed electro-magnetic
field device on one or more acupressure points daily for up to
4–8 weeks, significantly decreased fatigue (60). Similar positive
results were reported in another RCT (n= 33) conducted ear-
lier using the similar device (61). The clinical effects in these trials
were small and long-term follow-up data were lacking.
Summary
Exposure to pulsing, weak electromagnetic fields can alleviate
fatigue symptoms in pwMS, however, additional research is needed
into the feasibility and long-term use of these devices, due to
limited access and cost of devices.
BEHAVIORAL AND EDUCATIONAL INTERVENTIONS
Several published reviews and studies have examined the effective-
ness of various types of behavioral and/or educational interven-
tions for management of fatigue in pwMS, which included group
fatigue management programs, energy conservation programs,
and psychotherapies [e.g., cognitive behavioral therapy (CBT)
and mindfulness-based intervention]. A meta-analysis investi-
gated overall effectiveness of different types of educational pro-
grams on reducing the impact or severity of self-reported fatigue
in pwMS (11). The authors included eight RCTs, involving 662
pwMS. Educational interventions included a fatigue management
program, energy conservation programs, mindfulness interven-
tions, and CBT. The authors found significant global improvement
with a large pooled treatment ES for the educational interventions
of 0.54 (95% CI: 0.30–0.77 p< 0.001; range:−0.16 to 1.11) (11).
FATIGUE MANAGEMENT PROGRAMS (LEVEL II)
A number of structured fatigue management programs have been
explored in pwMS and most appeared effective in reducing fatigue.
A multi-centered parallel arm RCT (n= 164) evaluated the effec-
tiveness of a group-based program for managing MS-fatigue
[fatigue: applying cognitive behavioral and energy effectiveness
techniques to lifestyle (FACETS)], which was based upon a concep-
tual framework integrating elements from cognitive behavioral,
social-cognitive, energy effectiveness, self-management, and self-
efficacy theories (62). The program consisted of interactive group
sessions and activities (90-min sessions weekly for 6 weeks) and
was facilitated by two health professionals (such as occupational
therapists, nurses, or physiotherapists). The authors found sig-
nificant differences favoring the intervention group on fatigue
self-efficacy at 1 month follow-up (mean difference= 9; 95% CI 4–
14) with a large ES (ES= 0.54, p= 0.001). At 4 months follow-up,
the positive effects of the program still remained significant with
a moderate ES (ES= 0.36; p= 0.05; mean difference= 6; 95% CI
0–12). In addition, significant improvement in fatigue severity
was also found in the intervention group (p= 0.01) at 4 months
follow-up (62). In a 1-year follow-up study by the same authors,
the findings showed that the benefits of the FACETS program
for fatigue severity and self-efficacy were mostly sustained, with
a slight reduction in standardized ESs (ES=−0.29, p= 0.06 and
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0.34, p= 0.09, respectively) with additional significant improve-
ments in QoL (p= 0.046) (63). Another RCT (n= 51) evaluating
the efficacy of a MD fatigue management program in pwMS,
however, showed no efficacy in reducing the impact of fatigue
compared to a placebo intervention program (34). The MD fatigue
management program comprised interactive educational sessions
about possible strategies to manage fatigue and reduced energy
levels (2 h sessions weekly for 4 weeks).
Summary
A structured fatigue management program based on psychologi-
cal approaches delivered by health professionals can be effective
in reducing fatigue severity and increasing fatigue self-efficacy
for pwMS. It can be clinically beneficial and can be readily
incorporated into existing services.
ENERGY CONSERVATION INTERVENTIONS (LEVEL I)
A systematic review evaluated the effectiveness of energy con-
servation treatment for fatigue and QoL in pwMS (64). The
authors included six trials (four RCTs and two CCTs) involving
494 participants, which evaluated different energy conservation
interventions based on evidence-based protocols, which included
education about balancing, modifying and prioritizing activities,
rest, self-care, effective communication, biomechanics, ergonom-
ics, and environmental modification. The results were mixed due
to heterogeneity among the included studies. Meta-analysis of two
high-quality studies showed that energy conservation interven-
tions treatment was significantly more effective than no treatment
(waiting controls) in reducing the impact of fatigue and in improv-
ing QoL in the short-term. This was further supported by the
qualitative best-evidence synthesis of the other studies showing
moderate to strong evidence (64). There was no evidence that MD
fatigue management programs were more effective than placebo
for any fatigue-related outcome.
Summary
Energy conservation interventions can be effective in reducing
the impact of fatigue and improving QoL in pwMS in the short-
term. More high-quality RCTs are still needed to investigate the
usefulness of these treatments in the longer-term.
MINDFULNESS-BASED INTERVENTIONS (LEVEL I)
Mindfulness-based interventions have become increasingly pop-
ular in various areas of chronic disease management such as
depression, stroke, chronic pain, etc. (65). Mindfulness-based
interventions include a wide range of interventions, such as med-
itation, relaxation, and breathing techniques, yoga, Tai Chi, hyp-
nosis, visual imagery, and spirituality (55). There are few studies
evaluating the effects of the mindfulness-based approach in alle-
viating fatigue in pwMS. A recently published systematic review
of mindfulness-based interventions found only three trials (two
RCTs and one CCT) involving 183 participants (65). All trials
emphasized on mindful breath awareness, mindful movement,
and body awareness or “scanning.” All three studies measured
the effect of intervention on fatigue and found a significantly
beneficial effect of intervention on fatigue scores. One included
RCT found a significant post-intervention reduction in fatigue
in both the overall population and in subgroup analyses of
those with pre-intervention impairment. This beneficial effect was
maintained at 6 months (65).
Summary
Mindfulness-based interventions can be beneficial for fatigue
management in pwMS and are conceptually appealing. These
interventions could be considered in a patient management plan.
COGNITIVE AND PSYCHOLOGICAL INTERVENTIONS (LEVEL II)
Several studies have investigated cognitive training in pwMS aim-
ing mainly to improve attentional deficits, communication, and
memory (66). Overall evidence for beneficial effects of psycholog-
ical interventions in management of fatigue in pwMS is scarce. A
systematic review reported that cognitive behavioral approaches
were beneficial in the treatment of depression and in helping peo-
ple adjust to, and cope with having MS (66). However, the authors
did not find any studies focusing on psychological approaches to
managing fatigue in pwMS. Findings from a few studies evaluat-
ing fatigue as a secondary outcome showed inconclusive and/or
non-significant improvements in fatigue management (66).
A recent RCT (n= 40) showed that an internet-based cogni-
tive behavior therapy (CBT) program – “MS Invigor8” was an
effective treatment for MS-related fatigue (67). The CBT included
eight tailored, interactive sessions with a clinical psychologist over
8–10 weeks. The treatment group reported significantly greater
improvements in fatigue severity and impact as well as in anxi-
ety, depression and quality-adjusted life years (67). Another RCT
(n= 72) showed significantly greater improvements in fatigue in
pwMS after eight weekly sessions of CBT (p< 0.02) compared to
relaxation therapy (68). However, both groups showed clinically
significant decreases in fatigue. ESs for reduction in fatigue from
baseline to the end of treatment were 3.03 (95% CI 2.22–3.68) for
the CBT group across the 8 months compared with the relaxation
therapy group (ES 1.83; 95% CI 1.26–2.34) (68).
Summary
Psychological interventions, particularly CBT, can be a clinically
and cost-effective treatment for MS fatigue. There has been a
growing interest in these interventions as a means of empowering
patients, improving symptoms and overall quality of life. Addi-
tional studies are warranted, particularly those that include larger
numbers of people and longer term follow-up.
SUMMARY
Fatigue, a multidimensional, complex, and highly subjective symp-
tom, is one of the most frequent symptoms of MS patients. It is
associated with several factors or mechanisms. There is a con-
tinuing need for a comprehensive, multi-disciplinary long-term
management, which includes both pharmacological and non-
pharmacological interventions. This systematic review provides an
evidence-based overview of the effectiveness of different interven-
tions (pharmacological and non-pharmacological) currently used
to alleviate fatigue in pwMS. It highlights the lack of, method-
ologically robust trials to evaluate effectiveness of MS fatigue
management interventions.
Despite many interventions (both pharmacological and non-
pharmacological) used for the management of fatigue in pwMS,
effects of these vary considerably and any beneficial effect was at
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best modest and/or is yet to be established. Non-pharmacological
interventions (both exercise and psychological/educational inter-
ventions) appear to have a stronger and more significant favorable
effect on reducing the impact or severity of fatigue compared to
commonly prescribed pharmacological agents.
In conclusion, there is increasing awareness of the role of
both pharmacological and non-pharmacological interventions in
early and long-term management of fatigue in pwMS. Although
this review highlights the lack of high-quality studies evaluating
fatigue management strategies in pwMS (types, settings, compo-
nents, modalities, and duration of therapy), it adds to the existing
evidence by providing structured pre-defined “level of evidence”
to support different interventions for the management of fatigue
in this population. The findings from this review suggest that
non-pharmacological approaches used in isolation and/or in com-
bination with pharmacological agents should be the mainstay of
management of fatigue in pwMS. Further studies across the broad
range of interventions for the management of fatigue in MS are
warranted, using high-quality research approaches.
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